Plasma and Intracellular (Peripheral Blood Mononuclear Cells ...

1 downloads 0 Views 130KB Size Report
Jun 9, 2010 - Raltegravir is the first integrase approved for the treatment .... patients with no integrase inhibitor resistance-associated mu- tations, and a ...

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 2011, p. 72–75 0066-4804/11/$12.00 doi:10.1128/AAC.00789-10 Copyright © 2011, American Society for Microbiology. All Rights Reserved.

Vol. 55, No. 1

Plasma and Intracellular (Peripheral Blood Mononuclear Cells) Pharmacokinetics of Once-Daily Raltegravir (800 Milligrams) in HIV-Infected Patients䌤 Jose´ Molto ´,1,3* Marta Valle,2,3 David Back,4 Samandhy Ceden ˜o,5 Victoria Watson,4,6 Neill Liptrott,4,6 4,6 1 Deirdre Egan, Cristina Miranda, Manuel J. Barbanoj,2,3 and Bonaventura Clotet1,3,5 Lluita contra la Sida Foundation, HIV Clinic, Hospital Universitari Germans Trias i Pujol, Badalona, Spain1; Centre d’Investigacio ´ del Medicament, Institut de Recerca HSCSP, Servicio de Farmacología Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain2; Universitat Auto ´noma de Barcelona, Barcelona, Spain3; Pharmacology Research Laboratories, University of Liverpool, Liverpool, United Kingdom4; IrsiCaixa Foundation, HIV Clinic, Hospital Universitari Germans Trias i Pujol, Badalona, Spain5; and NIHR Biomedical Research Centre, Royal Liverpool and Broadgreen University Hospital Trust, Liverpool, United Kingdom6 Received 9 June 2010/Returned for modification 14 August 2010/Accepted 6 October 2010

The aim of this study was to evaluate the plasma and intracellular pharmacokinetics of raltegravir in HIV-infected patients receiving once-daily raltegravir. Five HIV-infected patients on stable therapy with lopinavir-ritonavir monotherapy whose HIV-1 RNA load was

Suggest Documents